<DOC>
	<DOCNO>NCT01456715</DOCNO>
	<brief_summary>Two human papillomavirus vaccine commercially available . No clinical data exist regard : - The immunogenicity safety Gardasil Twinrix co-administered . - The immunogenicity safety Cervarix administer subject previously vaccinate Gardasil . The main objective first phase clinical trial : • To assess compare immunogenicity Gardasil Twinrix Junior co-administered administer one month interval accord 0 , 6 month schedule 9-10 year-old girl . The main objective seconde phase clinical trial : • To determine effect booster dose Gardasil Cervarix HPV antibody give 42 month post-vaccination 9-10 year-old girl two dos Gardasil . Study Design &amp; Duration : Experimental Design : Blind third HPV vaccine dose , randomize , single centre study two treatment group . Duration study : Participants follow duration 10 year post-primary vaccination . Number Centres : One Center .</brief_summary>
	<brief_title>Immunogenicity Gardasil Twinrix Effect Dose Gardasil Cervarix Given 42 Months Later .</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>In 20082009 receive two dos Gardasil age 910 year accord 0 , 6 month schedule . Received less two dos Gardasil receive HPV vaccine outside study protocol .</criteria>
	<gender>Female</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Human Papillomavirus Vaccines</keyword>
	<keyword>Immunogenicity Gardasil Cervarix</keyword>
	<keyword>Booster dose</keyword>
</DOC>